Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD –

NEW YORK & BARCELONA, Spain–(BUSINESS WIRE)– Forest Laboratories, Inc. (FRX) and Almirall, S.A. (ALM.MC) announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza” Pressair” (aclidinium bromide inhalation powder) for the long …

Leave a Reply

Your email address will not be published. Required fields are marked *